IP Library › Granted Patent US 12,723,232
Granted Patent B2
US 12,723,232 · App. 17/633,082 · Granted Sep 1, 2026

Method for preparing skin-derived pluripotent precursor cells

Inventors: Yoriko Nakagiri (Utsunomiya, JP); Kiyotoshi Sekiguchi (Suita, JP)
Assignees: KAO CORPORATION; OSAKA UNIVERSITY
C12N5/063C12N2501/11C12N2501/115C12N2501/415C12N2501/998C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,723,232
App. No.
17/633,082
Granted
Sep 1, 2026
Kind
B2
Abstract

The present invention relates to improvement of the yield of skin-derived pluripotent precursor cells in induction of differentiation of stem cells to skin-derived pluripotent precursor cells. The present invention provides a method for preparing skin-derived pluripotent precursor cell comprising culturing a neural crest stem cells in the presence of at least one selected from the group consisting of laminin and a fragment thereof to differentiate the cells to skin-derived pluripotent precursor cells, wherein the laminin is at least one selected from the group consisting of laminin 111, laminin 121, laminin 332, laminin 421, laminin 511, laminin 521, and a variant thereof.

Claims (12)

1 . A method for preparing skin-derived pluripotent precursor cells, the method comprising:

culturing neural crest stem cells in the presence of a perlecan-modified laminin 111, a perlecan-modified laminin 121, a perlecan-modified laminin 332, a perlecan-modified laminin 421, a perlecan-modified laminin 511, a perlecan-modified laminin 521, or a combination thereof to differentiate the cells to skin-derived pluripotent precursor cells.

2 . The method according to claim 1 , further comprising preparing the neural crest stem cells,

wherein the preparation comprises culturing pluripotent stem cells in the presence of the perlecan-modified laminin 111, the perlecan-modified laminin 121, the perlecan-modified laminin 332, the perlecan-modified laminin 421, the perlecan-modified laminin 511, the perlecan-modified laminin 521, or a combination thereof to differentiate the cells to neural crest stem cells.

3 . The method according to claim 1 , wherein the culturing the neural crest stem cells in the presence of the perlecan-modified laminin 111, the perlecan-modified laminin 121, the perlecan-modified laminin 332, the perlecan-modified laminin 421, the perlecan-modified laminin 511, the perlecan-modified laminin 521, or a combination thereof comprises culturing the cells on a culture substrate comprising the perlecan-modified laminin 111, the perlecan-modified laminin 121, the perlecan-modified laminin 332, the perlecan-modified laminin 421, the perlecan-modified laminin 511, the perlecan-modified laminin 521, or a combination thereof or culturing the cells in a medium comprising the perlecan-modified laminin 111, the perlecan-modified laminin 121, the perlecan-modified laminin 332, the perlecan-modified laminin 421, the perlecan-modified laminin 511, the perlecan-modified laminin 521, or a combination thereof.

4 . The method according to claim 2 , wherein the culturing the pluripotent stem cells in the presence of the perlecan-modified laminin 111, the perlecan-modified laminin 121, the perlecan-modified laminin 332, the perlecan-modified laminin 421, the perlecan-modified laminin 511, the perlecan-modified laminin 521, or a combination thereof comprises culturing the cells on a culture substrate comprising the perlecan-modified laminin 111, the perlecan-modified laminin 121, the perlecan-modified laminin 332, the perlecan-modified laminin 421, the perlecan-modified laminin 511, the perlecan-modified laminin 521, or a combination thereof or culturing the cells in a medium comprising the perlecan-modified laminin 111, the perlecan-modified laminin 121, the perlecan-modified laminin 332, the perlecan-modified laminin 421, the perlecan-modified laminin 511, the perlecan-modified laminin 521, or a combination thereof.

5 . The method according to claim 1 , wherein the culturing neural crest stem cells comprises culturing the cells in a differentiation medium comprising a Wnt signaling agonist.

6 . The method according to claim 2 , wherein the culturing pluripotent stem cells comprises culturing the cells in a differentiation medium comprising at least one selected from the group consisting of TGFβ signal inhibitor and BMP signal inhibitor.

7 . The method according to claim 1 , wherein the skin-derived pluripotent precursor cells co-expresses nestin and fibronectin.

8 . The method according to claim 1 , wherein the neural crest stem cells are human-derived neural crest stem cells.

9 . The method according to claim 1 , wherein the culturing the cells is performed without using feeder cells.

10 . The method according to claim 1 , wherein the culturing the cells is performed in the absence of a xenogeneic component.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2023
From: NAKAGIRI, YORIKO; SEKIGUCHI, KIYOTOSHI
To: KAO CORPORATION; OSAKA UNIVERSITY
Reel/Frame 063108/0996 →
Priority Claims (1)
JP 2019-144899 · Aug 6, 2019 · national
Continuity (1)
Related Publication 20220340868A1 · Oct 27, 2022
References Cited (32)
US 8877493B2 · Sekiguchi et al. · 2014 [cited by applicant]
US 10000554B2 · Sekiguchi et al. · 2018 [cited by applicant]
US 10287541B2 · Sekiguchi et al. · 2019 [cited by applicant]
US 20120220031A1 · Sekiguchi et al. · 2012 [cited by applicant]
US 20140127806A1 · Sekiguchi et al. · 2014 [cited by applicant]
US 20170044495A1 · Nakagiri · 2017 [cited by applicant]
US 20190211305A1 · Eto et al. · 2019 [cited by applicant]
US 20190276804A1 · Sekiguchi et al. · 2019 [cited by applicant]
CN 106167790A · 2016 [cited by applicant]
JP 201178370A · 2011 [cited by applicant]
JP WO2012137970A1 · 2012 [cited by applicant]
JP 2015213495A · 2015 [cited by applicant]
WO WO2012137970A1 · 2012 [cited by examiner]
WO WO2018038242A1 · 2018 [cited by applicant]
WO WO2018088501A1 · 2018 [cited by applicant]
WO WO2018143312A1 · 2018 [cited by applicant]
Nakagawa, Masato, et al. “A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells.” Scientific reports 4.1 (2014): 3594. (Year: 2014). [cited by examiner]
Sugiyama-Nakagiri, Yoriko, Tsutomu Fujimura, and Shigeru Moriwaki. “Induction of skin-derived precursor cells from human induced pluripotent stem cells.” PloS one 11.12 (2016): e0168451. (Year: 2016). [cited by examiner]
Partial Supplementary European Search Report issued Jul. 5, 2023 in European Patent Application No. 20849572.1, 16 pages. [cited by applicant]
Sugiyama-Nakagiri et al., “Induction of Skin-Derived Precursor Cells from Human Induced Pluripotent Stem Cells”, PLOS ONE, vol. 11, No. 12, Dec. 19, 2016, pp. 1-13, XP093055708. [cited by applicant]
Shibata et al., “Selective Laminin-Directed Differentiation of Human Induced Pluripotent Stem Cells into Distinct Ocular Lineages”, Cell Reports, vol. 25, No. 6, Nov. 1, 2018, pp. 1668-1679 (Total pages 18), XP055650022. [cited by applicant]
International Search Report issued Oct. 6, 2020 in PCT/JP2020/029855 (submitting English translation only), 3 pages. [cited by applicant]
Jean G. Toma, et al., “Isolation of Multipotent Adult Stem Cells from the Dermis of Mammalian Skin” Nature Cell Biology, vol. 3, Sep. 2001, pp. 778-784. [cited by applicant]
Jeffrey Biernaskie, et al., “SKPs Derive from Hair Follicle Precursors and Exhibit Properties of Adult Dermal Stem Cells” Cell Stem Cell, vol. 5, Dec. 4, 2009, pp. 610-623. [cited by applicant]
Rebecca P. Hill, et al., “Generation and Characterization of Multipotent Stem Cells from Established Dermal Cultures” PLoS One, vol. 7, Issue 11, Nov. 2012, e50742, pp. 1-10. [cited by applicant]
Taniguchi, Yukimasa, et al., “Development of Cell Culture Substrate for Regenerative Medicine”, Biotechnology, vol. 96, No. 6, 2018, pp. 328-332 (with unedited computer generated English translation). [cited by applicant]
Lee, Gabsang. et al., “Derivation of Neural Crest Cells from Human Pluripotent Stem Cells” Nature Protocols, vol. 5, No. 4, 2010, pp. 688-701 and cover pages. [cited by applicant]
Extended European Search Report issued Sep. 21, 2023 in European Patent Application No. 20849572.1, 19 pages. [cited by applicant]
Lee, G., et al., “Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells”, Nature Biotechnology, vol. 25, No. 12, Dec. 1, 2007, XP002659606, pp. 1468-1475. [cited by applicant]
Higuchi, A., et al., “Polymeric design of cell culture materials that guide the differentiation of human pluripotent stem cells”, Progress in Polymer Science, vol. 65, Sep. 13, 2016, XP029897007, pp. 83-126. [cited by applicant]
Miyazaki, T. et al., Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nature Communications, vol. 3, No. 1236, Dec. 4, 2012, 10 pages, XP055055638. [cited by applicant]
Ohta et al., Laminin-guided highly efficient endothelial commitment from huma pluripotent stem cells. Scientific Reports, 6:35680; DOI:10.1038/srep35680, pp. 1-12, Published Nov. 2, 2016 (12 pages). [cited by applicant]